Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice

2022 ◽  
Author(s):  
Juan Vicente-Valor ◽  
Vicente Escudero-Vilaplana ◽  
Roberto Collado-Borrell ◽  
Sara Pérez-Ramírez ◽  
Cristina Villanueva-Bueno ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Drug Interactions

Drug–drug interactions with systemic antifungals in clinical practice

2007 ◽  
Vol 16 (11) ◽  
pp. 1227-1233 ◽  
Author(s):  
Fanny Depont ◽  
Frédéric Vargas ◽  
Hervé Dutronc ◽  
Emmanuelle Giauque ◽  
Jean-Marie Ragnaud ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Drug Interactions

Potential drug interactions between targeted oral antineoplastic agents and concomitant medication in clinical practice

2020 ◽  
Vol 19 (8) ◽  
pp. 1041-1048
Author(s):  
Vicente Escudero-Vilaplana ◽  
Roberto Collado-Borrell ◽  
Angela Hoyo-Muñoz ◽  
Alvaro Gimenez-Manzorro ◽  
Antonio Calles ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Drug Interactions ◽  
Antineoplastic Agents ◽  
Concomitant Medication ◽  
Potential Drug

scholarly journals Development and validation of a tool to assess the risk of QT drug-drug interactions in clinical practice

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Florine A. Berger ◽  
Heleen van der Sijs ◽  
Matthijs L. Becker ◽  
Teun van Gelder ◽  
Patricia M. L. A. van den Bemt
Keyword(s):  
Clinical Practice ◽  
Drug Interactions ◽  
Development And Validation

Potential drug-drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir ± DASABUVIR ± ribavirin in clinical practice

2018 ◽  
Vol 33 (5) ◽  
pp. 1100-1107 ◽  
Author(s):  
Elena González-Colominas ◽  
María-Carlota Londoño ◽  
Rosa M Morillas ◽  
Xavier Torras ◽  
Sergi Mojal ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Drug Interactions ◽  
Potential Drug

Update on New Antifungal Therapy

2007 ◽  
Vol 18 (3) ◽  
pp. 253-260 ◽  
Author(s):  
Paul Juang
Keyword(s):  
Clinical Practice ◽  
Adverse Effects ◽  
Drug Interactions ◽  
Clinical Efficacy ◽  
Antifungal Agents ◽  
Potent Inhibitor ◽  
Fungal Infections ◽  
Potential Drug ◽  
Glucan Synthase ◽  
Ergosterol Synthesis

Increases in rates as well as morbidity and mortality associated with fungal infections have necessitated the need for additional antifungal agents. Recent research has resulted in the introduction of 3 new antifungal agents: micafungin, anidulafungin, and posaconazole. Micafungin and anidulafungin, both potent inhibitor of 1,3-β-D-glucan synthase, are the second and third available agents in the echinocandins class that are available in clinical practice. Posaconazale, a potent inhibitor of ergosterol synthesis, is a new agent in the triazole class that has shown promising clinical efficacy in the treatment and prophylaxis of invasive fungal infections due to Candida as well as molds. This article reviews the clinical efficacy as well as the approved uses and dosages associated with the use of these new antifungal agents. Other considerations, such as precautions, administration techniques, potential drug interactions, and common adverse effects associated with the use of these agents, are also reviewed.

scholarly journals A cooperation project between hospital pharmacists and general practitioners about drug interactions in clinical practice

2017 ◽  
Vol 25 (6) ◽  
pp. 301-309
Author(s):  
Valeria Vinciguerra ◽  
Roberto Fantozzi ◽  
Clara Cena ◽  
Roberta Fruttero ◽  
Carla Rolle
Keyword(s):  
Clinical Practice ◽  
Drug Interactions ◽  
General Practitioners ◽  
Hospital Pharmacists ◽  
Cooperation Project

The relevance of drug–drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha1-blocker administration

2017 ◽  
Vol 23 (5) ◽  
pp. 467-469 ◽  
Author(s):  
Cristina Gervasoni ◽  
Chiara Resnati ◽  
Tiziana Formenti ◽  
Alessandro Fossati ◽  
Davide Minisci ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Drug Interactions ◽  
Protease Inhibitors
Sign in / Sign up

Export Citation Format

Share Document